|
Dr. Fahy received in his
M.D. degree from University College Dublin, Ireland
in 1985. After internal medicine training in Dublin,
he started a Pulmonary and Critical Care fellowship
at UCSF in 1989. He joined the faculty at UCSF in 1993
and became Associate Professor in 1999. He attends in
the ICU and in the outpatient chest faculty practice,
and he is actively involved in clinical research in
the division.
Dr Fahy is a member of
the asthma clinical research center at UCSF and works collaboratively
with Drs Boushey, Lazarus and Jansen in a number of multicenter
clinical trials. In addition, Dr Fahy has two areas of research
focus:
(1) Mucus hypersecretion
is an important cause of morbidity and mortality in asthma. Dr
Fahy has investigated mechanisms of mucus hypersecretion using
a variety of approaches in human subjects. One approach has been
to study concentrations of mucin glycoproteins and mucin secretagogues
in samples of induced sputum (mild and moderate asthma) and tracheal
aspirates (near fatal asthma). Another approach has been to apply
methods of quantitative morphometry to study stored mucin in the
epithelium and numbers of goblet cells in the epithelium in biopsies
obtained during bronchoscopy. Having established methods to measure
these outcomes, Dr Fahy's research group is currently examining
the effects of pro- and antiflammatory stimuli on these outcomes
in asthmatic subjects. Application of these methods to study the
efficacy of novel therapies directed at mucus hypersecretion is
a long-term goal of the laboratory.
(2) Transcriptional profiling
in airway samples collected by bronchoscopy: Dr Fahy's laboratory
has an important ongoing collaboration with Gregory Dolganov's
laboratory in the pulmonary division. He and Dr Dolganov are working
collaboratively to optimize methods for quantifying gene expression
in a variety of airway samples, including epithelial brushings
and homogenates of whole biopsies. In addition, he and Dr Dolganov
are using laser microdissection methods to obtain samples of cells
from tissues sections for the purposes of gene profiling in discrete
sub-compartments of the airway submucosa. The goal of this approach
is to enable gene profiling in subgroups of asthmatics with different
clinical phenotypes and different pathologic phenotype as defined
by stereology.
Ratto J, Wong H, Liu J, Fahy J, Boushey H, Solomon C, Balmes J. Effects of multiday exposure to ozone on airway inflammation as determined using sputum induction. Environ Health Perspect.2006;114:209-12.
Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol. 2006;117:1230-2.
Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, Dimango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E. Combination Therapy with a Long-acting {beta}-Agonist and a Leukotriene Antagonist in Moderate Asthma. Am J Respir Crit Care Med. 2006 Sep 14; Epub ahead of print.
Innes, AJ, Woodruff PG, Hays SR, Ferrando RE, Donnelly S, Lazarus SC, Fahy JV. Epithelial Mucin Stores are increased in the large airways of smokers with airflow obstruction. Chest 2006;130:1102-1108
Hays SR, Fahy JV. Characterizing mucous cell remodeling in cystic fibrosis: relationship to neutrophils. Am J Respir Crit Care Med. 2006 Nov. 1; 174(9): 1018-24. Epub 2006 Aug 17
Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fahy JV, Israel E, Lazarus SC, Lemanske RF Jr, Leone FT, Pesola GR, Peters SP, Sorkness CA, Szwejbka LA, Wechsler ME. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007 Jan;119(1):73-80.
|
